PCRX
Pacira BioSciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 ▼ 2 insiders sell $352.9K at $20.60
- Mar 17 ▼ 2 insiders sell $85.3K at $22.69
- Apr 20 to Apr 23 ▼ 4 days of insider sells: $628.2K by 1 insider, avg $25.13
- Jun 4 to Jun 11 ▼ 2 days of insider sells: $372.2K by 2 insiders, avg $22.73
- Aug 6 FDA: Pacira BioSciences Announces Publication of Positive Two-Y…
- Aug 17 ▼ 1 insider sell $70.6K at $23.23
- Oct 8 3 analyst actions
- Oct 8 ▼ 1 insider sell $217.9K at $36.32
- Oct 15 ▲ Short interest falls 47.3% to 4.26M
- Oct 30 ▲ Pacira BioSciences' board unanimously recommends that shareholders t…
- Nov 12 ▼ The Ninth Circuit reversed in part the District Court's judgment in…
- Nov 12 Viatris and its wholly owned subsidiary Peach Purchaser Sub Inc. fil…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $1.7M.
- InstitutionsBULLISH
Q3 2026: 24 added (0 new), 13 trimmed or exited.
- AnalystsMIXED
0 of 14 rate it Buy or better. Median target $36.50 (+0%).
- Short sellersCOVERING
Short interest −21.4% to 3.35M shares. 3.9 days to cover, ≈8.3% of shares.
- TrendUPTREND
16% above its 50-day average. New closing high $36.49 on Nov 10.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $11.3M |
| FMR LLC | ADD | $10.3M |
| VICTORY CAPITAL MANAGEMENT INC | ADD | $7.0M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | ADD | $6.9M |
| Empowered Funds, LLC | ADD | $6.6M |
| MARSHALL WACE, LLP | ADD | $6.0M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $4.7M |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | $4.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is inside the target range. Median implies +0%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 9, 2026 | Truist Securities DOWNGRADE | Hold |
| Oct 9, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 9, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Oct 8, 2026 | JP Morgan UPGRADE | Neutral |
| Oct 8, 2026 | Jefferies DOWNGRADE | Hold |
| Oct 8, 2026 | Needham DOWNGRADE | Hold |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Cross Shawn Chief Financial Officer Oct 30, 2026 | TAX W/H | $347.2K |
RIKER LAUREN Senior Vice President, Finance Oct 8, 2026 | EXERCISE | $194.1K |
RIKER LAUREN Senior Vice President, Finance Oct 8, 2026 | SELL | $217.9K |
SLONIN JONATHAN Chief Medical Officer Aug 17, 2026 | SELL | $70.6K |
RIKER LAUREN Senior Vice President, Finance Jun 11, 2026 | SELL | $143.7K |
Brege Laura Director Jun 10, 2026 | AWARD | 6,405 sh |
Froimson Mark Director Jun 10, 2026 | AWARD | 6,405 sh |
CHRISTIE CHRISTOPHER Director Jun 10, 2026 | AWARD | 6,405 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.73 | $0.65–$0.89 | -4.9% | $181.5M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Nov 16, 2026 | 🔒 Fresh data, subscribers only | |
SecBot reports
25 filings · 4 press releases · 5 bullish · 2 bearish · 7 mixed · 11 neutral- BEARISH 8-KNov 12, 2026
The Ninth Circuit reversed in part the District Court's judgment in Pacira's royalty dispute with…
Monitor for Pacira's next steps, including any petition for rehearing or certiorari, and for the District Court's recalculation of interest on remand. The resumption of royalty payments could…
- MIXED SC TO-T/ANov 12, 2026
Viatris and its wholly owned subsidiary Peach Purchaser Sub Inc. filed Amendment No. 1 to their…
The disclosure lawsuits are routine in M&A and unlikely to block the deal given the board's recommendation and the absence of a financing condition. Monitor for any preliminary injunction ruling…
- NEUTRAL SC 14D-9/ANov 12, 2026
Pacira BioSciences filed Amendment No. 2 to its Schedule 14D-9, updating the legal proceedings…
Monitor for any court rulings on preliminary injunctions that could delay or impose conditions on the tender offer closing by November 16. The volume of demand letters (15) suggests a coordinated…
- NEUTRAL 8-KNov 5, 2026
Pacira BioSciences will not issue its Q3 2026 earnings release or hold a conference call due to…
Monitor the tender offer conditions and regulatory approvals for the Viatris acquisition. The absence of Q3 earnings removes a near-term catalyst, and the stock will trade primarily on deal…
All PCRX filing & press-release reports (29)
- 8-K reportNov 12, 2026
- SC TO-T/A reportNov 12, 2026
- SC 14D-9/A reportNov 12, 2026
- 8-K reportNov 5, 2026
- SC 14D-9/A reportNov 3, 2026
- SC 13G/A reportOct 30, 2026
- SC 14D-9 reportOct 30, 2026
- SC TO-T reportOct 30, 2026
- SC 13D/A reportOct 13, 2026
- SC TO-C reportOct 8, 2026
- 144 reportOct 8, 2026
- 8-K reportOct 8, 2026
- SC TO-C reportOct 8, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 22, 2026
- 8-K reportJun 30, 2026
- CLUSTER reportJun 12, 2026
- DEFA14A reportJun 4, 2026
- 144 reportJun 4, 2026
- DEFA14A reportJun 1, 2026
- DEFA14A reportMay 27, 2026
- DEFA14A reportMay 26, 2026
- DEFA14A reportMay 20, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportApr 30, 2026
- PREC14A reportApr 17, 2026
- PRESS-RELEASE reportApr 13, 2026
- DEFA14A reportMar 11, 2026
- PRESS-RELEASE reportMar 11, 2026